Company intelligence / Profile preview

Resistell

Muttenz, Basel-Landschaft, Switzerlandresistell.com ↗

Ownership: Private
Employees: ~23
Development stage: Other

Overview

Resistell has developed a rapid phenotypic antibiotic susceptibility test (AST) based on nanomotion technology. Their clinical studies in bloodstream infections show over 95% accuracy compared to the gold standard with results in as little as 2–4 hours. The company’s device has CE IVD certification for three bacteria-antibiotic combinations and initial sales have begun for research use. Multi-site clinical validation studies are ongoing

Therapeutic areas: Infectious Diseases
Modalities: Device
Industry: Metabolite Diagnostics

Partnerships

Cellectric and Lausanne University Hospital (Eurostars project on cystic fibrosis)iM4TB Foundation (tuberculosis drug macozinone testing partnership)Pfizer AG grant-supported study

Beyond the preview

Go deeper on Resistell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Resistell.

Explore the full profile